Renalytix (RENX) Share Price, News & Analysis

Company Overview

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

Key Stats

• Today's Range: 7.50 to 8.25
• 50-Day Range: 7.25 to 9.29
• 52-Week Range: 6.50 to 20
• Volume: 21,788 shs
• Average Volume: 207,229 shs
• Market Capitalization: £31.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RENX Stock Analysis - Frequently Asked Questions

How have RENX shares performed this year?

Renalytix's stock was trading at GBX 11 on January 1st, 2025. Since then, RENX shares have decreased by 31.8% and is now trading at GBX 7.50.
View the best growth stocks for 2025 here.

How were Renalytix's earnings last quarter?

Renalytix Plc (LON:RENX) issued its quarterly earnings data on Tuesday, October, 1st. The company reported ($31.00) EPS for the quarter. Renalytix had a negative net margin of 1,191.75% and a positive trailing twelve-month return on equity of 293.20%.

How do I buy shares of Renalytix?

Shares of RENX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Renalytix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Renalytix investors own include AutoZone (AZO), Beyond Meat (BYND), Helium One Global (HE1), HSBC (HSBA), Intel (INTC), ITM Power (ITM) and JD Sports Fashion (JD).

Company Calendar

• Last Earnings: 10/01/2024
• Today: 5/25/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: LON:RENX
• CIK: N/A
• Web: www.renalytixai.com
• Phone: 44 20 3139 2910
• Fax: N/A
• Employees: 102
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (21.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-109,928,962.31
• Net Margins: -1,191.75%
• Pretax Margin: N/A
• Return on Equity: 293.20%
• Return on Assets: -93.54%

Debt

• Debt-to-Equity Ratio: -72.91
• Current Ratio: 0.24
• Quick Ratio: 2.42

Sales & Book Value

• Annual Sales: £9.22 million
• Price / Sales: 3.37
• Cash Flow: GBX 4.09 per share
• Price / Cash Flow: 1.84
• Book Value: GBX (10.71) per share
• Price / Book: -0.70

Miscellaneous

• Outstanding Shares: 414,527,492
• Free Float: N/A
• Market Cap: £31.09 million
• Optionable: Not Optionable
• Beta: 2.10